The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Antibiotics for Emerging Pathogens
Open accessAbstract
Toward New Scaffolds: Most existing antibiotics are derived from a small number of core molecular structures or scaffolds. As more and more pathogens emerge that are resistant to existing antibiotics, Fischbach and Walsh (p. 1089 ) review why renewed efforts must be made to find not only new antibiotics but new scaffolds. Approaches in the areas of natural products, synthesis, and target-based discovery are all yielding promising antibiotics candidates. The battle against resistance should also involve researching narrow-spectrum antibiotics and using combination therapies to extend the usefulness of drugs with high intrinsic resistance rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
Molecular Basis of Bacterial Outer Membrane Permeability Revisited
Nikaido, H. (2003) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.67.4.593-656.2003 · Cited by 4,316
Klevens, R. M. (2007) · JAMA · doi:10.1001/jama.298.15.1763 · Cited by 3,726
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
Li, J. W.-H., & Vederas, J. C. (2009) · Science · doi:10.1126/science.1168243 · Cited by 2,052
How many antibiotics are produced by the genus Streptomyces ?
Watve, M., Tickoo, R., Jog, M., & Bhole, B. (2001) · Archives of Microbiology · doi:10.1007/s002030100345 · Cited by 923
Genetic Analysis of a High-Level Vancomycin-Resistant Isolate of Staphylococcus aureus
Weigel, L. M., Clewell, D. B., Gill, S. R., Clark, N. C., McDougal, L. K., Flannagan, S. E., Kolonay, J. F., Shetty, J., Killgore, G. E., & Tenover, F. C. (2003) · Science · doi:10.1126/science.1090956 · Cited by 889
Platensimycin is a selective FabF inhibitor with potent antibiotic properties
Wang, J., Soisson, S. M., Young, K., Shoop, W., Kodali, S., Galgoci, A., Painter, R., Parthasarathy, G., Tang, Y. S., Cummings, R., et al. (2006) · Nature · doi:10.1038/nature04784 · Cited by 812
Experimental Determination and System Level Analysis of Essential Genes in Escherichia coli MG1655
Gerdes, S. Y., Scholle, M. D., Campbell, J. W., Balázsi, G., Ravasz, E., Daugherty, M. D., Somera, A. L., Kyrpides, N. C., Anderson, I., Gelfand, M. S., et al. (2003) · Journal of Bacteriology · doi:10.1128/jb.185.19.5673-5684.2003 · Cited by 725
Lipid II as a target for antibiotics
Breukink, E., & de Kruijff, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2004 · Cited by 701
Pathogenic fungus harbours endosymbiotic bacteria for toxin production
Partida-Martinez, L. P., & Hertweck, C. (2005) · Nature · doi:10.1038/nature03997 · Cited by 677
Antibacterial Natural Products in Medicinal Chemistry—Exodus or Revival?
von Nussbaum, F., Brands, M., Hinzen, B., Weigand, S., & Häbich, D. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600350 · Cited by 672
New antibiotics from bacterial natural products
Clardy, J., Fischbach, M. A., & Walsh, C. T. (2006) · Nature Biotechnology · doi:10.1038/nbt1266 · Cited by 615
Self-citationMetabolites from symbiotic bacteria
Piel, J. (2009) · Nat. Prod. Rep. · doi:10.1039/b703499g · Cited by 577
Recognition of Antimicrobial Peptides by a Bacterial Sensor Kinase
Bader, M. W., Sanowar, S., Daley, M. E., Schneider, A. R., Cho, U., Xu, W., Klevit, R. E., Le Moual, H., & Miller, S. I. (2005) · Cell · doi:10.1016/j.cell.2005.05.030 · Cited by 567
Dysregulation of bacterial proteolytic machinery by a new class of antibiotics
Brötz-Oesterhelt, H., Beyer, D., Kroll, H.-P., Endermann, R., Ladel, C., Schroeder, W., Hinzen, B., Raddatz, S., Paulsen, H., Henninger, K., et al. (2005) · Nature Medicine · doi:10.1038/nm1306 · Cited by 505
A Cholesterol Biosynthesis Inhibitor Blocks Staphylococcus aureus Virulence
Liu, C.-I., Liu, G. Y., Song, Y., Yin, F., Hensler, M. E., Jeng, W.-Y., Nizet, V., Wang, A. H.-J., & Oldfield, E. (2008) · Science · doi:10.1126/science.1153018 · Cited by 490
Bacterial Protection of Beetle-Fungus Mutualism
Scott, J. J., Oh, D.-C., Yuceer, M. C., Klepzig, K. D., Clardy, J., & Currie, C. R. (2008) · Science · doi:10.1126/science.1160423 · Cited by 478
An Inhibitor of FtsZ with Potent and Selective Anti-Staphylococcal Activity
Haydon, D. J., Stokes, N. R., Ure, R., Galbraith, G., Bennett, J. M., Brown, D. R., Baker, P. J., Barynin, V. V., Rice, D. W., Sedelnikova, S. E., et al. (2008) · Science · doi:10.1126/science.1159961 · Cited by 452
Nathan, C. (2004) · Nature · doi:10.1038/431899a · Cited by 410
Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens
Brinster, S., Lamberet, G., Staels, B., Trieu-Cuot, P., Gruss, A., & Poyart, C. (2009) · Nature · doi:10.1038/nature07772 · Cited by 317
Bister, B., Bischoff, D., Ströbele, M., Riedlinger, J., Reicke, A., Wolter, F., Bull, A. T., Zähner, H., Fiedler, H., & Süssmuth, R. D. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200353160 · Cited by 309
A Convergent Enantioselective Route to Structurally Diverse 6-Deoxytetracycline Antibiotics
Charest, M. G., Lerner, C. D., Brubaker, J. D., Siegel, D. R., & Myers, A. G. (2005) · Science · doi:10.1126/science.1109755 · Cited by 298
Actinonin, a Naturally Occurring Antibacterial Agent, Is a Potent Deformylase Inhibitor
Chen, D. Z., Patel, D. V., Hackbarth, C. J., Wang, W., Dreyer, G. B., Young, D. C., Margolis, P. S., Wu, C., Ni, Z.-J., Trias, J., et al. (2000) · Biochemistry · doi:10.1021/bi992245y · Cited by 298
Cho, S. H., Warit, S., Wan, B., Hwang, C. H., Pauli, G. F., & Franzblau, S. G. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00055-06 · Cited by 292
A global assembly line for cyanobactins
Donia, M. S., Ravel, J., & Schmidt, E. W. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.84 · Cited by 279
Baltz, R. H. (2006) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-005-0077-9 · Cited by 246
Genome Mining for Novel Natural Product Discovery
Challis, G. L. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm700948z · Cited by 231
Tigecycline: A New Glycylcycline for Treatment of Serious Infections
Noskin, G. A. (2005) · Clinical Infectious Diseases · doi:10.1086/431672 · Cited by 226
Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria
Falagas, M. E., Bliziotis, I. A., Kasiakou, S. K., Samonis, G., Athanassopoulou, P., & Michalopoulos, A. (2005) · BMC Infectious Diseases · doi:10.1186/1471-2334-5-24 · Cited by 224
Drug discovery from natural products
Gullo, V. P., McAlpine, J., Lam, K. S., Baker, D., & Petersen, F. (2006) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-006-0107-2 · Cited by 222
Boguski, M. S., Mandl, K. D., & Sukhatme, V. P. (2009) · Science · doi:10.1126/science.1169920 · Cited by 220
Davidovich, C., Bashan, A., Auerbach-Nevo, T., Yaggie, R. D., Gontarek, R. R., & Yonath, A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700041104 · Cited by 196
From magic bullets back to the Magic Mountain: the rise of extensively drug-resistant tuberculosis
Dorman, S. E., & Chaisson, R. E. (2007) · Nature Medicine · doi:10.1038/nm0307-295 · Cited by 189
Harnessing the Power of the Genome in the Search for New Antibiotics
Rosamond, J., & Allsop, A. (2000) · Science · doi:10.1126/science.287.5460.1973 · Cited by 186
A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore
Miller, J. R., Dunham, S., Mochalkin, I., Banotai, C., Bowman, M., Buist, S., Dunkle, B., Hanna, D., Harwood, H. J., Huband, M. D., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811275106 · Cited by 159
Freiberg, C., Fischer, H. P., & Brunner, N. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.749-759.2005 · Cited by 105
Singh, S. B., Phillips, J. W., & Wang, J. (2007) · PubMed · Cited by 63
When will the genomics investment pay off for antibacterial discovery?
Mills, S. D. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.11.025 · Cited by 58
Garau, J., Wilson, W. R., Wood, M., & Carlet, J. M. (1997) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.1997.tb00649.x · Cited by 52
Ceftizoxime and other third-generation cephalosporins: structure-activity relationships
Dunn, G. L. (1982) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/10.suppl_c.1 · Cited by 46
Research works printed but not linked: 11
- C. Walsh Antibiotics: Actions Origins Resistance [American Society for Microbiology (ASM) Press Washington DC 2003].
- Nathan C., Goldberg F. M., Nat. Rev. Drug Discovery 4, 887 (2005). · doi:10.1038/nrd1878
- 10.1164/rccm.200801-132OC · doi:10.1164/rccm.200801-132oc
- Neu H. C., Fu K. P., Antimicrob. Agents Chemother. 13, 584 (1978).666290 · doi:10.1128/aac.13.4.584
- 10.1093/jac/10.1.1 · doi:10.1093/jac/10.1.1
- Wenzel S. C., Muller R., Curr. Opin. Drug Discov. Dev. 12, 220 (2009).
- McAlpine J. B., J. Nat. Prod. 72, 566 (2009). · doi:10.1021/np800742z
- 10.1038/ja.2006.74 · doi:10.1038/ja.2006.74
- Baltz R. H., SIM News 55, 186 (2005).
- Singh S. B., Phillips J. W., Wang J., Curr. Opin. Drug Discov. Dev. 10, 160 (2007).
- 10.1073/pnas.0510077103 · doi:10.1073/pnas.0510077103
Cited by
Antibacterial drug discovery in the resistance era
Brown, E. D., & Wright, G. D. (2016) · Nature · doi:10.1038/nature17042 · Cited by 2,247
Antimicrobial Resistance in ESKAPE Pathogens
De Oliveira, D. M. P., Forde, B. M., Kidd, T. J., Harris, P. N. A., Schembri, M. A., Beatson, S. A., Paterson, D. L., & Walker, M. J. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00181-19 · Cited by 2,078
Zhao, X., Wu, H., Guo, B., Dong, R., Qiu, Y., & Ma, P. X. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.01.011 · Cited by 1,971
Antibiotics and Bacterial Resistance in the 21st Century
Fair, R. J., & Tor, Y. (2014) · Perspectives in Medicinal Chemistry · doi:10.4137/pmc.s14459 · Cited by 1,955
Platforms for antibiotic discovery
Lewis, K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3975 · Cited by 1,445
Metadata
- Authors
- Fischbach, M. A., & Walsh, C. T.
- Venue
- Science
- Published
- 2009-08-28
- Volume
- 325
- Issue
- 5944
- Pages
- 1089-1093
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1970798262
- Cited by
- 1,777
- References
- 42
- FWCI
- 73.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.